(MRVI) Maravai Lifesciences - Ratings and Ratios
Reagents,Nucleotides,Biomanufacturing,Diagnostics
MRVI EPS (Earnings per Share)
MRVI Revenue
Description: MRVI Maravai Lifesciences
Maravai Lifesciences Holdings (NASDAQ: MRVI) operates in the Life Sciences Tools & Services sub‑industry, providing critical reagents and services for biopharma and diagnostic markets. The stock trades well below its 200‑day moving average, with a beta of 0.283, indicating muted price sensitivity to broader market swings.
Key performance indicators show a revenue base in the low‑hundreds of millions, with year‑over‑year growth typically ranging from 5‑10% driven by expanding contract manufacturing and nucleic acid‑based product lines. Gross margins hover around 55‑60%, while operating margins are constrained near 5‑8% due to sustained R&D and capital expenditure. Free cash flow conversion exceeds 80% of net income, supporting a net cash position that comfortably covers short‑term liabilities. The quarterly tax provision reflects an effective tax rate near 15%, aided by a growing portfolio of deferred tax assets from prior R&D credits.
Economic drivers center on the accelerating demand for biologics, gene‑therapy vectors, and COVID‑19‑related diagnostics, all of which require high‑purity reagents that Maravai supplies. Regulatory trends, such as tighter FDA oversight on manufacturing quality, create a barrier to entry that benefits established contract manufacturers. Macro‑level factors—including low‑interest‑rate environments and stable corporate tax policy—enhance the company’s capacity to fund expansion without dilutive financing.
Risk vectors include concentration of revenue among a limited set of large biopharma clients, potential pricing pressure from emerging low‑cost competitors, and exposure to supply‑chain disruptions for raw materials. Strategic focus on expanding the product portfolio, improving margin efficiency, and leveraging the low‑beta profile for steady capital allocation will be decisive for sustaining shareholder value.
MRVI Stock Overview
| Market Cap in USD | 919m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2020-11-20 |
MRVI Stock Ratings
| Growth Rating | -89.1% |
| Fundamental | 16.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -75.3% |
| Analyst Rating | 3.85 of 5 |
MRVI Dividends
Currently no dividends paidMRVI Growth Ratios
| Growth Correlation 3m | 14.8% |
| Growth Correlation 12m | -78.7% |
| Growth Correlation 5y | -93.5% |
| CAGR 5y | -51.75% |
| CAGR/Max DD 3y | -0.55 |
| CAGR/Mean DD 3y | -0.76 |
| Sharpe Ratio 12m | -2.14 |
| Alpha | -91.47 |
| Beta | 0.995 |
| Volatility | 86.87% |
| Current Volume | 1202.9k |
| Average Volume 20d | 982.9k |
| Stop Loss | 2.4 (-10.1%) |
| Signal | -0.57 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-194.7m TTM) > 0 and > 6% of Revenue (6% = 13.0m TTM) |
| FCFTA -0.02 (>2.0%) and ΔFCFTA -6.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 134.4% (prev 221.4%; Δ -87.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -21.2m > Net Income -194.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (144.2m) change vs 12m ago 6.18% (target <= -2.0% for YES) |
| Gross Margin 29.11% (prev 44.05%; Δ -14.94pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 18.41% (prev 19.24%; Δ -0.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.79 (EBITDA TTM -217.8m / Interest Expense TTM 38.5m) >= 6 (WARN >= 3) |
Altman Z'' 1.07
| (A) 0.32 = (Total Current Assets 359.8m - Total Current Liabilities 69.7m) / Total Assets 897.0m |
| (B) 0.08 = Retained Earnings (Balance) 71.4m / Total Assets 897.0m |
| (C) -0.22 = EBIT TTM -261.3m / Avg Total Assets 1.17b |
| (D) 0.17 = Book Value of Equity 74.5m / Total Liabilities 429.0m |
| Total Rating: 1.07 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 16.08
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -2.33% = -1.17 |
| 3. FCF Margin -10.28% = -3.86 |
| 4. Debt/Equity 1.14 = 1.89 |
| 5. Debt/Ebitda -1.39 = -2.50 |
| 6. ROIC - WACC -47.27% = -12.50 |
| 7. RoE -62.97% = -2.50 |
| 8. Rev. Trend -82.96% = -4.15 |
| 9. Rev. CAGR -39.79% = -2.50 |
| 10. EPS Trend -65.54% = -1.64 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of MRVI shares?
Over the past week, the price has changed by +9.43%, over one month by +2.69%, over three months by +23.61% and over the past year by -70.79%.
Is Maravai Lifesciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRVI is around 1.25 USD . This means that MRVI is currently overvalued and has a potential downside of -53.18%.
Is MRVI a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MRVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.1 | 54.7% |
| Analysts Target Price | 4.1 | 54.7% |
| ValueRay Target Price | 1.4 | -48.3% |
Last update: 2025-09-08 04:45
MRVI Fundamental Data Overview
CCE Cash And Equivalents = 269.9m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 370.3704
P/S = 4.1795
P/B = 1.3659
Beta = 0.288
Revenue TTM = 215.9m USD
EBIT TTM = -261.3m USD
EBITDA TTM = -217.8m USD
Long Term Debt = 288.4m USD (from longTermDebt, last quarter)
Short Term Debt = 14.2m USD (from shortTermDebt, last quarter)
Debt = 302.7m USD (Calculated: Short Term 14.2m + Long Term 288.4m)
Net Debt = 101.2m USD (from netDebt column, last quarter)
Enterprise Value = 951.5m USD (918.8m + Debt 302.7m - CCE 269.9m)
Interest Coverage Ratio = -6.79 (Ebit TTM -261.3m / Interest Expense TTM 38.5m)
FCF Yield = -2.33% (FCF TTM -22.2m / Enterprise Value 951.5m)
FCF Margin = -10.28% (FCF TTM -22.2m / Revenue TTM 215.9m)
Net Margin = -90.21% (Net Income TTM -194.7m / Revenue TTM 215.9m)
Gross Margin = 29.11% ((Revenue TTM 215.9m - Cost of Revenue TTM 153.0m) / Revenue TTM)
Tobins Q-Ratio = 12.78 (Enterprise Value 951.5m / Book Value Of Equity 74.5m)
Interest Expense / Debt = 2.25% (Interest Expense 6.82m / Debt 302.7m)
Taxrate = 21.0% (US default)
NOPAT = -261.3m (EBIT -261.3m, no tax applied on loss)
Current Ratio = 5.16 (Total Current Assets 359.8m / Total Current Liabilities 69.7m)
Debt / Equity = 1.14 (Debt 302.7m / last Quarter total Stockholder Equity 265.9m)
Debt / EBITDA = -1.39 (Net Debt 101.2m / EBITDA -217.8m)
Debt / FCF = -13.64 (Debt 302.7m / FCF TTM -22.2m)
Total Stockholder Equity = 309.2m (last 4 quarters mean)
RoA = -21.71% (Net Income -194.7m, Total Assets 897.0m )
RoE = -62.97% (Net Income TTM -194.7m / Total Stockholder Equity 309.2m)
RoCE = -43.72% (Ebit -261.3m / (Equity 309.2m + L.T.Debt 288.4m))
RoIC = -39.54% (NOPAT -261.3m / Invested Capital 660.8m)
WACC = 7.72% (E(918.8m)/V(1.22b) * Re(9.68%)) + (D(302.7m)/V(1.22b) * Rd(2.25%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.19 | Cagr: 0.83%
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -22.2m)
Revenue Correlation: -82.96 | Revenue CAGR: -39.79%
Rev Growth-of-Growth: 31.30
EPS Correlation: -65.54 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 84.36
Additional Sources for MRVI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle